Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 3
2008 2
2009 1
2010 3
2011 1
2012 1
2013 3
2014 1
2016 5
2017 2
2018 3
2019 2
2020 5
2021 2
2022 8
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: klarenbeek s. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Nature. 2022. PMID: 35948633 Free PMC article. Clinical Trial.
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.
Zhang Z, Kong X, Ligtenberg MA, van Hal-van Veen SE, Visser NL, de Bruijn B, Stecker K, van der Helm PW, Kuilman T, Hoefsmit EP, Vredevoogd DW, Apriamashvili G, Baars B, Voest EE, Klarenbeek S, Altelaar M, Peeper DS. Zhang Z, et al. Among authors: klarenbeek s. Cell Rep Med. 2022 Jun 21;3(6):100655. doi: 10.1016/j.xcrm.2022.100655. Epub 2022 Jun 9. Cell Rep Med. 2022. PMID: 35688159 Free PMC article.
CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.
Houthuijzen JM, de Bruijn R, van der Burg E, Drenth AP, Wientjens E, Filipovic T, Bullock E, Brambillasca CS, Pulver EM, Nieuwland M, de Rink I, van Diepen F, Klarenbeek S, Kerkhoven R, Brunton VG, Scheele CLGJ, Boelens MC, Jonkers J. Houthuijzen JM, et al. Among authors: klarenbeek s. Nat Commun. 2023 Jan 12;14(1):183. doi: 10.1038/s41467-023-35793-w. Nat Commun. 2023. PMID: 36635273 Free PMC article.
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J, Yemelyanenko J, Chao X, Klarenbeek S, Opdam M, Malka Y, Hoekman L, Kruger D, Bleijerveld O, Brambillasca CS, Sprengers J, Siteur B, Annunziato S, van Haren MJ, Martin NI, van de Ven M, Peters D, Agami R, Linn SC, Boven E, Altelaar M, Jonkers J, Zingg D, Wessels LFA. Bhin J, et al. Among authors: klarenbeek s. J Exp Med. 2023 Nov 6;220(11):e20211743. doi: 10.1084/jem.20211743. Epub 2023 Aug 29. J Exp Med. 2023. PMID: 37642941 Free PMC article.
Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism.
Gan C, Wang J, Martínez-Chávez A, Hillebrand M, de Vries N, Beukers J, Wagenaar E, Wang Y, Lebre MC, Rosing H, Klarenbeek S, Ali RB, Pritchard C, Huijbers I, Beijnen JH, Schinkel AH. Gan C, et al. Among authors: klarenbeek s. Acta Pharm Sin B. 2023 Feb;13(2):618-631. doi: 10.1016/j.apsb.2022.10.017. Epub 2022 Oct 25. Acta Pharm Sin B. 2023. PMID: 36873183 Free PMC article.
Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors.
Blomberg OS, Kos K, Spagnuolo L, Isaeva OI, Garner H, Wellenstein MD, Bakker N, Duits DEM, Kersten K, Klarenbeek S, Hau CS, Kaldenbach D, Raeven EAM, Vrijland K, Kok M, de Visser KE. Blomberg OS, et al. Among authors: klarenbeek s. Oncoimmunology. 2023 Apr 13;12(1):2201147. doi: 10.1080/2162402X.2023.2201147. eCollection 2023. Oncoimmunology. 2023. PMID: 37089449 Free PMC article.
Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development.
Gan C, Wang J, Wang Y, Martínez-Chávez A, Hillebrand M, de Vries N, Beukers J, Lebre MC, Wagenaar E, Rosing H, Klarenbeek S, Bleijerveld OB, Song JY, Altelaar M, Beijnen JH, Schinkel AH. Gan C, et al. Among authors: klarenbeek s. Biomed Pharmacother. 2023 Aug;164:114956. doi: 10.1016/j.biopha.2023.114956. Epub 2023 May 31. Biomed Pharmacother. 2023. PMID: 37267638 Free article.
Cell-free DNA levels are increased in acute graft-versus-host disease.
Kroeze A, Cornelissen AS, Pascutti MF, Verheij M, Bulder I, Klarenbeek S, Ait Soussan A, Hazenberg MD, Nur E, van der Schoot CE, Voermans C, Zeerleder SS. Kroeze A, et al. Among authors: klarenbeek s. Eur J Haematol. 2022 Sep;109(3):271-281. doi: 10.1111/ejh.13806. Epub 2022 Jun 30. Eur J Haematol. 2022. PMID: 35617105
45 results